Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing for preclinical research. The company states it conducts studies in accordance with Good Laboratory Practice (GLP) and the Animal Welfare Act, relying on third parties to perform this testing. Its lead product, ZTALMY (ganaxolone), was approved by the FDA in 2022; preclinical data cited in its development included animal studies assessing reproductive toxicity and other long-term effects.

The company's foundational research and regulatory submissions for its central nervous system disorder treatments are predicated on data from animal models. For example, published research related to its drug candidate includes studies measuring drug effects on pain-depressed behaviors in mice. This places the company within the broad pharmaceutical sector practice of using animal testing to establish drug safety and efficacy, a core activity triggering the animal exploitation exclusion.